Cargando…
Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
PURPOSE: BIBF 1120 is a potent triple angiokinase inhibitor now being evaluated in many types of tumors. We examine the antitumor effects of BIBF 1120 on nasopharyngeal carcinoma (NPC) in vitro and in vivo. MATERIALS AND METHODS: The effect of BIBF 1120 on NPC cell proliferation was evaluated using...
Autores principales: | Xue, Cong, Tian, Ying, Zhang, Jing, Zhao, Yuanyuan, Zhan, Jianhua, Fang, Wenfeng, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801128/ https://www.ncbi.nlm.nih.gov/pubmed/27042009 http://dx.doi.org/10.2147/DDDT.S96634 |
Ejemplares similares
-
Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012) -
BIBF1120 Protects against Diabetic Retinopathy through Neovascularization-Related Molecules and the MAPK Signaling Pathway
por: Cao, Xin, et al.
Publicado: (2023) -
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
por: Gori, Bruno, et al.
Publicado: (2011) -
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011) -
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120
por: Fazio, Grazia, et al.
Publicado: (2022)